Big Potential in Cancer Immunotherapy
While there are a number of new treatments being developed to improve chemotherapy through its actual delivery or through its ability to specifically target cancer cells, cancer immunotherapy could be an entirely different level of safety and efficacy for cancer patients.
Pharma Deals North of $10B Seen Returning in 2013
Big pharma companies such as Pfizer, Johnson & Johnson and Merck & Co. may be back in the hunt for big-dollar acquisitions. The J.P. Morgan Healthcare Conference, held in San Francisco last week, saw a number of companies looking "to get a sense of available and competing assets," according to a Bloomberg News report. The report goes on to note that big pharma is also "on the hunt for assets to fill revenue holes left by expired patents."
OPKO Health Expands Collaboration with Bristol-Myers Squibb
OPKO Health Inc. has expanded its collaboration with Bristol-Myers Squibb for the company's diagnostic test technology. OPKO's simple blood tests are being developed to identify biomarkers for a wide variety of diseases, including neurodegenerative disorders and various malignancies.
'Cautious Optimism' Expressed at the J.P. Morgan Healthcare Conference
Broadly speaking, as far down as the industry tumbled with the economic crash a few years back, folks are starting to see brief bits of sunshine and are hoping for more.
Supreme Court Ensures Funding of Research Using Human Embryonic Stem Cells
Embryonic stem cell researchers were reported to be "jubilant" after the U.S. Supreme Court refused to consider a case that would have blocked National Institutes of Health research using the cells. The case was brought by two adult stem cell researchers seeking to "to emancipate human embryos from research slavery sponsored by the NIH."
M&A Buzz: Pharma Deals Worth North of $1B May Return in 2013
Pharmaceutical companies including Pfizer Inc. and Bristol-Myers Squibb Co. have spent the last several years digesting earlier acquisitions, refocusing product development and setting aside cash in anticipation of expiring patents. Now, the expectation is they're are ready to start buying again.
7 Biotech Trends for the Coming Year
What does 2013 hold for the biotech industry? America didn't fall off the fiscal cliff when the clock struck midnight on New Year's Eve, yet 2013 still presents numerous challenges for the biopharma industry to overcome. Genetic Engineering and Biotechnology News has compiled a list of some key biopharma developments likely to shape the coming 12 months.
Planning a big night out? Eating asparagus could prevent that nasty hangover
Drinking milk, eating bread, water before bed; the list of hangover prevention methods is extensive. However, new research suggests that tucking into a few asparagus shoots before a big night out may be all that is required.
Genentech's cancer-fighting T-DM1 leads the FDA's Class of 2013
T-DM1's chances for earlier-than-expected approval rest in the fact that a lot is already known about one piece of the so-called antibody-drug conjugate. T-DM1 couples Genentech's blockbuster cancer drug Herceptin with a chemotherapy agent developed by ImmunoGen Inc.
Top 5 New Year's resolutions for the medical device industry include passing the comparative effectiveness test
Selling to physicians and being paid on the basis of how many widgets sold is so 20th century. The new world order demands evidence of how well a medical device works and whether it reduces the cost of care. Industry leaders have to figure out where their products fit in a system where wellness is a priority.